InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Kelly Michael Aaron, Director. Insider active across 4 companies, notably DMC Global Inc.. Cumulatively, 19 filings have been recorded. Split: 1 buy · 0 sell. Total volume traded: €34k. History available since 12 May 2021. The latest transaction was filed on 13 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Kelly Michael Aaron
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
16,937 shares0Common StockSEC:0001769668-26-000002:0
72,468 shares@ US$14.500.022% mcap100.0% of flowCommon StockSEC:0001193125-26-182271:0
20,414 shares0Common StockSEC:0000950170-25-083218:0
12,254 shares0Common StockSEC:0001077183-25-000128:0
5,000 shares@ US$7.60100.0% of flowCommon StockSEC:0001077183-25-000112:0
Canonical exit: 25 Aug 2025 (T+90)
17,580 shares0Common StockSEC:0000034067-25-000104:0
5,518 shares0Common StockSEC:0000034067-25-000034:0
11,336 shares0Common StockSEC:0001077183-24-000131:0
11,847 shares0Common StockSEC:0000950170-24-071005:0
9,520 shares0Common StockSEC:0000034067-24-000085:0
8,584 shares0Common StockSEC:0001209191-23-036429:0
7,086 shares0Common StockSEC:0000034067-23-000097:0
15,556 shares0Common StockSEC:0001077183-22-000113:0
12,671 shares0Common StockSEC:0001209191-22-035831:0
5,006 shares0Common StockSEC:0000034067-22-000076:0
4,610 shares0Common StockSEC:0001567619-21-012874:0
10,115 shares0Common StockSEC:0001209191-21-040387:0
3,081 shares0Common StockSEC:0001077183-21-000161:0
1,888 shares0Common StockSEC:0000034067-21-000077:0
19 of 19 declarations
About Kelly Michael Aaron
Michael Aaron Kelly is a Director at DMC Global Inc., Neogenomics Inc., and Amicus Therapeutics, Inc. In this role, he participates in strategic decision-making and the direction of operations for these companies. Kelly brings his expertise to guide growth and innovation initiatives, thereby contributing to the success of each organization.
